US 12,359,002 B2
Heterodimeric antibodies that bind CD3 and tumor antigens
Matthew Bernett, Monrovia, CA (US); Gregory Moore, Azusa, CA (US); John Desjarlais, Pasadena, CA (US); Seung Chu, Cypress, CA (US); Rumana Rashid, Temple City, CA (US); Umesh Muchhal, Monrovia, CA (US); and Sung-Hyung Lee, San Gabriel, CA (US)
Assigned to Xencor, Inc., Pasadena, CA (US)
Filed by Xencor, Inc., Pasadena, CA (US)
Filed on Apr. 27, 2023, as Appl. No. 18/308,623.
Application 18/308,623 is a continuation of application No. 17/124,371, filed on Dec. 16, 2020, granted, now 11,673,972.
Application 17/124,371 is a continuation of application No. 14/952,714, filed on Nov. 25, 2015, granted, now 10,889,653, issued on Jan. 12, 2021.
Claims priority of provisional application 62/251,005, filed on Nov. 4, 2015.
Claims priority of provisional application 62/250,971, filed on Nov. 4, 2015.
Claims priority of provisional application 62/159,111, filed on May 8, 2015.
Claims priority of provisional application 62/085,117, filed on Nov. 26, 2014.
Claims priority of provisional application 62/085,027, filed on Nov. 26, 2014.
Claims priority of provisional application 62/085,106, filed on Nov. 26, 2014.
Claims priority of provisional application 62/084,908, filed on Nov. 26, 2014.
Prior Publication US 2023/0365717 A1, Nov. 16, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/30 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/468 (2013.01) [C07K 16/2809 (2013.01); C07K 16/2818 (2013.01); C07K 16/2896 (2013.01); C07K 16/30 (2013.01); C07K 16/3061 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/515 (2013.01); C07K 2317/52 (2013.01); C07K 2317/522 (2013.01); C07K 2317/526 (2013.01); C07K 2317/528 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/60 (2013.01); C07K 2317/622 (2013.01); C07K 2317/64 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 2 Claims
 
1. A heterodimeric antibody comprising:
a) a first monomer comprising:
i) a first variable heavy domain,
ii) a first constant heavy chain comprising a first Fc domain, and
iii) a scFv comprising a scFv variable light domain, a scFv linker and a scFv variable heavy domain; wherein said scFv is covalently attached to the C-terminus of said Fc domain using a domain linker;
b) a second monomer comprising a second variable heavy domain and a second constant heavy chain comprising a second Fc domain;
c) a first common light chain comprising a variable light domain and a constant light domain; and
d) a second common light chain comprising a variable light domain and a constant light domain,
wherein said first and said second Fc domains have a set of amino acid substitutions selected from the group consisting of S364K/E357Q:L368D/K370S; L368D/K370S:S364K; L368E/K370S:S364K; T411E/K360E/Q362E:D401K; L368D/K370S:S364K/E357L and K370S:S364K/E357Q,
wherein said first variable heavy domain and said variable light domain of said first common light chain bind a first antigen, said second variable heavy domain and said variable light domain of said second common light chain bind said first antigen, and said scFv binds a second antigen, and
wherein said heterodimeric antibody is a trivalent antibody.